Delivery Order SPE2DB22D3019-SPE2DB25FK4HM
- Not listed
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $11,573.00. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a $17,791.36 delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of June 27, 2025, and performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe eczema, asthma, and chronic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $6,695.03 under firm fixed price terms. This is a non-set-aside competitive award with an ultimate completion date of July 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema,...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a $16,727.99 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of September 4, 2025, and performance to be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $13,293.08. This firm fixed-price delivery order, which is effective through August 27, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $80,099.53 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This is a non-set-aside contract with an ultimate completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK4HMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $153,667.62 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 26, 2025. This firm fixed-price delivery order, with an ultimate completion date of September 29, 2025, represents a non-set-aside competitive award to the prime contractor's corporate office located in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions, making this acquisition part of the Defense Health Agency's pharmaceutical supply needs for military beneficiaries and healthcare systems. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor vehicle extending through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs. The company's federal contracting profile demonstrates consistent success in competing for medical procurement through the Defense Logistics Agency's Medical Supply Chain, positioning it as a critical vendor for federal pharmaceutical distribution across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $153.7k | 9/26/25 |